Related references
Note: Only part of the references are listed.Palbociclib (PD-0332991), a selective CDK4/6 inhibitor, restricts tumour growth in preclinical models of hepatocellular carcinoma
Julien Bollard et al.
GUT (2017)
Immune Checkpoint in Glioblastoma: Promising and Challenging
Jing Huang et al.
FRONTIERS IN PHARMACOLOGY (2017)
Targeting Cyclin-Dependent Kinases in Synovial Sarcoma: Palbociclib as a Potential Treatment for Synovial Sarcoma Patients
Myrella Vlenterie et al.
ANNALS OF SURGICAL ONCOLOGY (2016)
Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo
Zhen Tao et al.
CLINICAL CANCER RESEARCH (2016)
Palbociclib: A new hope in the treatment of breast cancer
R. Priyadharsini Palanisamy
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2016)
Co-delivery of erlotinib and doxorubicin by pH-sensitive charge conversion nanocarrier for synergistic therapy
Yongju He et al.
JOURNAL OF CONTROLLED RELEASE (2016)
Phase I trial of palbociclib, a selective cyclin dependent kinase 4/6 inhibitor, in combination with cetuximab in patients with recurrent/metastatic head and neck squamous cell carcinoma
Loren Michel et al.
ORAL ONCOLOGY (2016)
Erlotinib induces the human non-small-cell lung cancer cells apoptosis via activating ROS-dependent JNK pathways
Fenglian Shan et al.
CANCER MEDICINE (2016)
Cancer Statistics, 2015
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2015)
Synergistic Induction of Erlotinib-Mediated Apoptosis by Resveratrol in Human Non-Small-Cell Lung Cancer Cells by Down-Regulating Survivin and Up-Regulating PUMA
Peipei Nie et al.
CELLULAR PHYSIOLOGY AND BIOCHEMISTRY (2015)
The cyclin-dependent kinase 4/6 inhibitor palbociclib in combination with letrozole versus letrozole alone as first-line treatment of oestrogen receptor-positive, HER2-negative, advanced breast cancer (PALOMA-1/TRIO-18): a randomised phase 2 study
Richard S. Finn et al.
LANCET ONCOLOGY (2015)
The history and future of targeting cyclin-dependent kinases in cancer therapy
Uzma Asghar et al.
NATURE REVIEWS DRUG DISCOVERY (2015)
Phase II trial of erlotinib during and after radiotherapy in children with newly diagnosed high-grade gliomas
Ibrahim Qaddoumi et al.
FRONTIERS IN ONCOLOGY (2014)
The Somatic Genomic Landscape of Glioblastoma
Cameron W. Brennan et al.
CELL (2013)
Phase II Trial of the CDK4 Inhibitor PD0332991 in Patients With Advanced CDK4-Amplified Well-Differentiated or Dedifferentiated Liposarcoma
Mark A. Dickson et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Glioma and glioblastoma - how much do we (not) know?
Ivana Jovcevska et al.
MOLECULAR AND CLINICAL ONCOLOGY (2013)
CDK4/6 inhibition antagonizes the cytotoxic response to anthracycline therapy
A. Kathleen McClendon et al.
CELL CYCLE (2012)
Differential Sensitivity of Glioma-versus Lung Cancer-Specific EGFR Mutations to EGFR Kinase Inhibitors
Igor Vivanco et al.
CANCER DISCOVERY (2012)
Phase II trial of erlotinib with temozolomide and radiation in patients with newly diagnosed glioblastoma multiforme
David M. Peereboom et al.
JOURNAL OF NEURO-ONCOLOGY (2010)
Pattern of retinoblastoma pathway inactivation dictates response to CDK4/6 inhibition in GBM
W. Ruprecht Wiedemeyer et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
Kimmo J. Hatanpaa et al.
NEOPLASIA (2010)
The EGFRvIII variant in glioblastoma multiforme
Hui K. Gan et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2009)
Therapeutic Inhibition of the Epidermal Growth Factor Receptor in High-Grade Gliomas: Where Do We Stand?
Georg Karpel-Massler et al.
MOLECULAR CANCER RESEARCH (2009)
Epidermal growth factor receptor inhibitors in neuro-oncology: Hopes and disappointments
Alba A. Brandes et al.
CLINICAL CANCER RESEARCH (2008)
Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma
J. F. de Groot et al.
JOURNAL OF NEURO-ONCOLOGY (2008)
Comprehensive genomic characterization defines human glioblastoma genes and core pathways
L. Chin et al.
NATURE (2008)
Malignant astrocytic glioma: genetics, biology, and paths to treatment
Frank B. Furnari et al.
GENES & DEVELOPMENT (2007)
被撤回的出版物: Erlotinib, an effective epidermal growth factor receptor tyrosine kinase inhibitor, induces p27KIP1 up-regulation and nuclear translocation in association with cell growth inhibition and G1/S phase arrest in human non-small-cell lung cancer cell lines (Retracted article. See vol. 88, pg. 390, 2015)
Yi-He Ling et al.
MOLECULAR PHARMACOLOGY (2007)
Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: The Tarceva Lung Cancer Investigation Trial
Ulrich Gatzemeier et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Erlotinib induces cell cycle arrest and apoptosis in hepatocellular cancer cells and enhances chemosensitivity towards cytostatics
A Huether et al.
JOURNAL OF HEPATOLOGY (2005)
Living with or without cyclins and cyclin-dependent kinases
CJ Sherr et al.
GENES & DEVELOPMENT (2004)
Share Paper
